Tempest Therapeutics (TPST) AI Stock Analysis

• Market Cap: $14.19M
• Dividend Yield: N/A
• Average Volume (3M): 50.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: N/A
• EPS Growth: 49.43%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.79
• Shares Outstanding: 4,927,161
• 10 Day Avg. Volume: 57,939
• 30 Day Avg. Volume: 50,791
• PEG Ratio: 0.34
• Price to Book (P/B): 15.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.05
• Enterprise Value/Market Cap: 1.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -152.20
• Enterprise Value/Ebitda: -0.57
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $3.00 ▲(2.74% Upside)

The score is primarily constrained by weak financial performance (no revenue, sizable losses, heavy cash burn, and a reduced equity cushion). Technicals also weigh heavily due to a clear downtrend across all major moving averages and negative MACD. Valuation provides limited support given the negative P/E and no dividend, while the Nasdaq noncompliance notice adds an additional risk factor.

Positive Factors

Pipeline expansion: dual-CAR T acquisition

Acquiring clinical-stage dual-targeting CD19/BCMA CAR-T assets broadens modality exposure and clinical diversity, adding an asset (TPST-2003) aimed at extramedullary disease. This materially increases long-term strategic optionality and potential milestone-driven de-risking for a small clinical-stage biotech.

Completed registered direct offering and warrants

A successful registered direct offering with a healthcare-focused institutional investor provides fresh capital and shows investor appetite. The proceeds, though modest, materially reduce near-term financing pressure, extending runway and enabling planned clinical activities and integration work tied to recent asset additions.

Leadership change and strategic focus

A new CEO and a stated strategic-alternatives process signal active management intent to reposition the company and extract value. Durable benefits include clearer execution accountability for clinical and M&A integration, and potential acceleration of partnership or licensing outcomes that can reshape long-term prospects.

Negative Factors

Pre-revenue with substantial cash burn

The company remains pre-revenue with persistent, sizable operating losses and heavy free cash outflows. This structural cash burn creates ongoing dependency on external financing, elevates dilution risk, constrains multi-year trial programs, and limits flexibility to fund unforeseen development costs without material capital raises.

Eroded equity and shrinking asset base

A sharply reduced equity cushion and declining assets weaken the company’s balance-sheet resilience. This lowers protection against adverse clinical or market outcomes, increases borrowing or dilution likelihood, and reduces negotiating leverage with partners or acquirers over the medium term.

Nasdaq noncompliance notice and governance lapse

A Nasdaq noncompliance notice highlights governance and operational control shortcomings. Delisting risk or remediation obligations can impair liquidity, complicate future capital raises, and deter institutional partners, making sustained access to public markets and strategic transactions more difficult until resolved.

Tempest Therapeutics Business Overview & Revenue Model

Company Description

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

How the Company Makes Money

Tempest Therapeutics makes money primarily through the development and potential commercialization of its therapeutic candidates. The company typically earns revenue through licensing agreements, collaboration partnerships, and milestone payments from larger pharmaceutical companies. These partnerships often involve joint development and commercialization efforts, where Tempest may receive upfront payments, research funding, and royalties from future sales of successfully developed drugs. Additionally, the company may secure funding from grants and public or private investments to support its research and clinical trials.

Tempest Therapeutics Financial Statement Overview

Summary

Tempest Therapeutics is in the growth stage typical for a biotech company, with no revenues and high expenditures leading to losses. Financial stability shows some signs of improvement, but heavy reliance on external financing and lack of operational cash flow remain significant risks.

Income Statement

Tempest Therapeutics has consistently recorded no revenue over the years, which is typical for many early-stage biotechnology companies. Although gross profit and net income are negative, showing the company is not yet profitable, it's important to note that this aligns with the industry's norm where R&D expenditures often outweigh revenues in initial phases.

Balance Sheet

The company's debt-to-equity ratio is somewhat high, indicating a reliance on debt financing. However, the equity ratio is improving, signaling potential strengthening of the financial position. Stockholders' equity has fluctuated over the years, with recent improvements, which is positive, but the overall financial stability remains a concern.

Cash Flow

Operating and free cash flows remain negative, reflecting ongoing cash burn typical for the sector. The company has managed to secure financing consistently, which has supported cash flow but highlights reliance on external funding. The lack of any significant positive cash flow from operations poses a risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-133.00K	-389.00K	0.00	0.00	0.00	-815.00K
EBITDA	-35.35M	-40.14M	-27.66M	-33.45M	-26.65M	-18.39M
Net Income	-36.05M	-41.84M	-29.49M	-35.71M	-28.30M	-19.12M
Balance Sheet
Total Assets	17.13M	41.49M	51.60M	46.09M	73.24M	22.86M
Cash, Cash Equivalents and Short-Term Investments	7.51M	30.27M	39.23M	31.23M	51.83M	18.82M
Total Debt	8.40M	15.37M	20.66M	22.11M	18.54M	2.44M
Total Liabilities	10.78M	22.36M	24.84M	27.98M	37.12M	91.66M
Stockholders Equity	6.35M	19.13M	26.77M	18.11M	36.12M	-68.79M
Cash Flow
Free Cash Flow	-33.40M	-33.46M	-27.53M	-31.63M	-26.09M	-19.07M
Operating Cash Flow	-33.40M	-33.03M	-27.36M	-31.07M	-25.96M	-19.02M
Investing Cash Flow	-3.00K	-435.00K	-170.00K	-562.00K	-97.00K	-6.00K
Financing Cash Flow	18.44M	24.50M	35.60M	11.40M	59.06M	34.60M

Tempest Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 2.92 is below the 20-day moving average (MA) of 2.97, below the 50-day MA of 5.25, and below the 200-day MA of 7.58, indicating a bearish trend. The MACD of -0.56 indicates Negative momentum. The RSI at 30.97 is Neutral, neither overbought nor oversold. The STOCH value of 24.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.

Tempest Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LTRN	52 Neutral	$37.92M	-1.93	-104.58%	―	―	1.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PDSB	51 Neutral	$54.35M	-1.21	-221.81%	―	―	29.95%
CALC	51 Neutral	$76.80M	-3.32	-526.36%	―	―	-2.46%
MRSN	48 Neutral	$145.36M	-2.06	―	―	-4.76%	8.09%
ATNM	45 Neutral	$44.61M	-1.29	-133.09%	―	11.11%	20.65%
TPST	43 Neutral	$14.19M	-0.29	-405.03%	―	―	49.43%

Tempest Therapeutics Corporate Events

Tempest Therapeutics Faces Nasdaq Noncompliance, Plans Annual Meeting

Tempest Therapeutics disclosed that on January 8, 2026 it received a notice from Nasdaq’s Listing Qualifications Department stating the company was not in compliance with Nasdaq’s continued listing rules because it failed to hold an annual shareholders’ meeting within twelve months of its December 31, 2024 fiscal year end. The company has already scheduled its 2025 Annual Meeting of Stockholders for January 27, 2026, and under Nasdaq rules it has until February 23, 2026 to regain compliance or submit a remediation plan, with a potential extension to June 29, 2026; holding the January 27 meeting is expected to restore compliance and reduce the near-term risk to its Nasdaq listing status for shareholders.

The most recent analyst rating on (TPST) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Tempest Therapeutics Secures $4.25M in Direct Offering

On November 24, 2025, Tempest Therapeutics entered into a securities purchase agreement with a healthcare-focused institutional investor to issue and sell shares of common stock and warrants in a registered direct offering and a concurrent private placement. The offering, expected to close on November 26, 2025, is anticipated to generate gross proceeds of approximately $4.25 million, with potential additional proceeds from warrant exercises. The company plans to use the funds for working capital and general corporate purposes, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (TPST) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Tempest Therapeutics Announces New Leadership and Acquisition

Tempest Therapeutics, Inc. has entered into an Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc., involving the acquisition of assets related to CAR T-cell therapies. The transaction, expected to close in early 2026, will result in significant changes in the company’s leadership, with Dr. Matt Angel appointed as CEO and President. The deal includes the issuance of shares and warrants, and is subject to stockholder approval and other conditions.

The most recent analyst rating on (TPST) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.